抗肝癌合剂对荷肝癌H22小鼠肿瘤细胞周期的影响

摘要

Objective To observe the effect of melting agent of anti-liver cancer(MAALC) on the tumor growth and the mitotic cycle of H22 tumor-bearing mouse model. Methods Sixty KM mice were randomly divided into model group, low-dose, mid-dose, and high-dose MAALC groups, 5-FU group, and mid-dose MAALC+5-FU group. All mice were inoculated with the H22 liver cancer cell at right armpit, then treated with the corresponding medicine for 10 d. And then all mice were killed to detach the tumor. The detached tumors were weighted and the inhibitory rate were calculated. The mitotic cycle of tumor cells was analyzed by flowcytometry and the prolifer-ation index were calculated. Results The inhibitory rates low-dose, mid-dose, and high-dose MAALC groups, 5-FU group and MAALC+5-FU group were 0.64%, 15.17%, 15.08%, 64.86%, 66.33%. Compared with that in model group (1.3217±0.2929g), the average tumor in low-dose MAALC group was not different (1.3133±0.2840, P>0.05), but that in mid-dose and high-dose MAALC groups were lighter (1.1212±0.1928, 1.1224±0.1772, P<0.05); no sig-nificant difference was found between the two groups (P>0.05); that in 5-FU group and MAALC+5-FU group were significant lighter (0.4645±0.0923, 0.4450±0.1085, P<0.01). MAALC hindered the tumor cell in the G0/G1 phase, that is, the G0/G1 cells increased, while the S and G2/M cells correspondingly decreased. Compared with that in model group (69.10%±4.39%), the proliferation index in mid-dose MAALC, high-dose MAALC, 5-FU, and MAALC+5-FU groups (56.60%±7.87%, 54.30%±7.08%, 47.61%±9.66%, 40.83%±9.92%; P<0.05 or P<0.01) were significantly lower except for that in low-dose MAALC group (64.18%±8.35%, P>0.05). Conclusion MAALC can obviously restrain the growth of tumor and hinder the tumor cell in the G0/G1 phase.%目的：观察抗肝癌合剂对荷肝癌H22小鼠移植瘤的生长及肿瘤细胞周期分布的影响。方法60只昆明小鼠随机分为模型组、抗肝癌合剂高、中、低剂量组、氟尿嘧啶组（5-FU组）和抗癌合剂中剂量+氟尿嘧啶组（中剂量+5-FU组），将H22腹水型瘤细胞悬液接种至昆明小鼠右腋窝皮下制备局灶性肿瘤模型，分组灌胃给药。10天后，小鼠剥离移植瘤，称取瘤重，计算抑瘤率，流式细胞仪检测分析细胞周期情况，计算细胞增殖指数。结果抑瘤率：抗肝癌合剂低、中、高剂量组及5-Fu组、中剂量+5-Fu组分别为0.64%、15.17%、15.08%、64.86%、66.33%；平均瘤重：低剂量组与模型组无明显差异[（1.3133±0.2840）g 比（1.3217±0.2929）g，P>0.05]；中、高剂量组比模型对照组降低[（1.1212±0.1928）g、（1.1224±0.1772）g 比（1.3217±0.2929）g，P<0.05]，但两组间无差异[（1.1212±0.1928）g比（1.1224±0.1772）g，P>0.05]；5-Fu组、中剂量+5-Fu组比模型对照组降低[（0.4645±0.0923）g、（0.4450±0.1085）g比（1.3217±0.2929）g，P<0.01]；各用药组均能使肿瘤组织细胞阻滞于G0/G1期，表现为G0/G1期细胞增多，S、G2/M期细胞相应减少，细胞增殖指数PI各用药组均小于模型对照组，低剂量组与模型对照组比较差异无统计学意义[（64.18±8.35）%比（69.10±4.39）%，P>0.05]；其余各组与模型对照组比较[（56.60±7.87）%、（54.30±7.08）%、（47.61±9.66）%、（40.83±9.92）%比（69.10±4.39）%]差异有统计学意义（P<0.05或P<0.01）。结论抗肝癌合剂对荷肝癌H22小鼠肿瘤的生长有明显的抑制作用，使肿瘤组织细胞阻滞于G0/G1期。